Log in

Relevant bibliographies by topics / Glioblastoma Multiforme (WHO grade IV) / Journal articles

To see the other types of publications on this topic, follow the link: Glioblastoma Multiforme (WHO grade IV).

Journal articles on the topic 'Glioblastoma Multiforme (WHO grade IV)'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Glioblastoma Multiforme (WHO grade IV).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Litak, Jakub, Wiesława Grajkowska, Justyna Szumiło, et al. "PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme." Brain Sciences 11, no. 2 (2021): 262. http://dx.doi.org/10.3390/brainsci11020262.

Full text

Abstract:

High-grade gliomas are infrequent in the pediatric population compared to adults, nevertheless, mortality and morbidity caused by malignant gliomas in this group of patients remain significant. PD-L1 and PD-1 Immune checkpoints (IC) molecules maintain immunological balance between activation and suppression. Eighteen patients with a histopathological diagnosis of pediatric glioblastoma multiforme (GBM, WHO IV) were studied. In total, PD-L1 expression was detected in 8 patients (44%). The molecular aspect of IC and immunotherapy targeted on PD-1/PD-L1 axis in pediatric population may be a promi

APA, Harvard, Vancouver, ISO, and other styles

2

Faulkner, Kalli, Blythe Bowman, and Jeffrey Sosnowski. "Glioblastoma Multiforme (Gliosarcoma) WHO Grade IV With Osteosarcomatous Differentiation: A Case Study." American Journal of Clinical Pathology 138, suppl 1 (2012): A005. http://dx.doi.org/10.1093/ajcp/138.suppl1.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sánchez-Prieto, Lucía, and Ángel M. Cuesta. "Immunotherapy in action: Innovative strategies against glioblastoma multiforme." Anales de la Real Academia Nacional de Farmacia, no. 91(01) (March 31, 2025): 45–65. https://doi.org/10.53519/analesranf.2025.91.01.02.

Full text

Abstract:

Glioblastoma multiforme (GBM) is the most common type of brain tumor in adults, with an annual incidence around 1/33,330 and a prevalence estimated at 1/100,000. This is the reason why Orphanet has cataloged it as a rare disease. Moreover, it is classified by the World Health Organization (WHO) as astrocytoma grade IV. It is well known to be an aggressive tumor, and this is why, although its treatment combines surgery, radiotherapy, and chemotherapy, the life expectancy of those who suffer from it doesn’t reach 14 months. The bad efficiency of the therapy is due to the molecular characteristic

APA, Harvard, Vancouver, ISO, and other styles

4

Delgado, Benjamin J., Leila Moosavi, Ericka Rangel, et al. "An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female." Journal of Investigative Medicine High Impact Case Reports 7 (January 2019): 232470961986825. http://dx.doi.org/10.1177/2324709619868255.

Full text

Abstract:

Primary spinal cord giant cell glioblastoma multiforme of the thoracic spinal cord is a rarely-diagnosed primary spinal cord tumor in comparison to neoplasms in intracranial locations. In this article, we highlight a young adult who was diagnosed with intramedullary giant cell glioblastoma, IDH wild-type, World Health Organization grade IV/IV of the thoracic spinal cord. This case report describes the treatment approach with a postsurgical combination of radiation therapy and temozolomide, which resulted in the patient to return to her baseline of health only to later develop neurological symp

APA, Harvard, Vancouver, ISO, and other styles

5

Shawki, Omar, Salman Shaikh, Soumya Mukherjee, Hussien El-Maghraby, and Ronan Dardis. "SURVIVAL OVER A DECADE IN A CASE OF GLIOBLASTOMA." Neuro-Oncology 25, Supplement_3 (2023): iii21. http://dx.doi.org/10.1093/neuonc/noad147.092.

Full text

Abstract:

Abstract AIMS Glioblastoma multiforme is the most aggressive type of primary brain tumours, but there is a small percentage of patients who have a long-term survival and some exceptional cases who survive decades after surgical removal of tumour along with adjuvant therapy. METHOD In 2011, a 40-year-old man, presented with headaches & confusion and underwent gliolan guided resection of a right frontal glioblastoma WHO grade IV. He received 30# of 60Gy Radiotherapy with TMZ. Chemotherapy was continued with interval scans in 2016 and 2018 showing stable disease. MRI scan in October 2022 show

APA, Harvard, Vancouver, ISO, and other styles

6

Lagiou, Anthoula, Ioannis Papagiannopoulos, Nikoletta Margari, and Georgios Vasilopoulos. "Epidemiological - clinical features of primary malignant brain tumors of patients who underwent surgical resection and / or radiotherapy." Health & Research Journal 1, no. 1 (2015): 56. http://dx.doi.org/10.12681/healthresj.19286.

Full text

Abstract:

The aim of the present study was to describe the demographic characteristics of patients diagnosed with primary brain tumor, the clinical features and prognostic indicators of disease progression and treatment they received.Methods: A retrospective descriptive study was conducted on a convenience sample of 47 patients who attended the radiotherapeutic department of General Hospital of Athens over three years, from May 2011 until May 2014.For analysis used the statistical program SPSS 18.0.Results: 59.6% of patients were male and 40.4% of patients were between 61 and 69 years. 85.1% of patients

APA, Harvard, Vancouver, ISO, and other styles

7

Michael, Justin S., Bong-Seop Lee, Miqin Zhang, and John S. Yu. "Nanotechnology for treatment of glioblastoma multiforme." Journal of Translational Internal Medicine 6, no. 3 (2018): 128–33. http://dx.doi.org/10.2478/jtim-2018-0025.

Full text

Abstract:

Abstract Glioblastoma multiforme (GBM), a grade IV astrocytoma as defined by the World Health Organization (WHO) criteria, is the most common primary central nervous system tumor in adults. After treatment with the current standard of care consisting of surgical resection, concurrent temozolomide (TMZ), and radiation, the median survival is only 15 months. The limited and less-effective treatment options for these highly aggressive GBMs call for the development of new techniques and the improvement of existing technologies. Nanotechnology has shown promise in treating this disease, and some na

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Zhongyu, Zhiqiang Yao, Chao Li, Yicheng Lu, and Chunfang Gao. "Gene Expression Profiling in Human High-Grade Astrocytomas." Comparative and Functional Genomics 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/245137.

Full text

Abstract:

Diffuse astrocytoma of (WHO grade II) has a tendency to progress spontaneously to anaplastic astrocytoma (WHO grade III) and/or glioblastoma (WHO grade IV). However, the molecular basis of astrocytoma progression is still poorly understood. In current study, an essential initial step toward this goal is the establishment of the taxonomy of tumors on the basis of their gene expression profiles. We have used gene expression profiling, unsupervised (hierarchal cluster (HCL) and principal component analysis (PCA)) and supervised (prediction analysis for microarrays (PAM)) learning methods, to demo

APA, Harvard, Vancouver, ISO, and other styles

9

Woźnicki, Paweł, Dorota Bartusik-Aebisher, Agnieszka Przygórzewska, and David Aebisher. "Immunological Insights into Photodynamic Therapy of Glioblastoma Multiforme." Molecules 30, no. 15 (2025): 3091. https://doi.org/10.3390/molecules30153091.

Full text

Abstract:

The Gliomas account for 81% of all malignant central nervous system tumors and are classified by WHO into four grades of malignancy. Glioblastoma multiforme (GBM), the most common grade IV glioma, exhibits an extremely aggressive phenotype and a dismal five-year survival rate of only 6%, underscoring the urgent need for novel therapeutic approaches. Immunotherapy has emerged as a promising strategy, and photodynamic therapy (PDT) in particular has attracted attention for its dual cytotoxic and immunostimulatory effects. In GBM models, PDT induces immunogenic cell death characterized by the rel

APA, Harvard, Vancouver, ISO, and other styles

10

Syed, Aaqid Siraj, Sanjana Sehgal, Sanjeev K. Pandey, Brijesh K. Tiwari, Ranjit Kumar, and Meenu Gupta. "Primary spinal glioblastoma multiforme: a case report." International Surgery Journal 11, no. 6 (2024): 1023–26. http://dx.doi.org/10.18203/2349-2902.isj20241410.

Full text

Abstract:

Spinal cord glioblastoma multiforme (GBM) is an uncommon disease within spinal tumours. According to our review of literature, less than 200 patients have been reported so far. Here we highlight the case of a 35 year female who complained of mild and intermittent lower back pain that radiates to bilateral thighs and was associated with tingling and numbness over both feet. The patient was evaluated and operated elsewhere with L1-L2 laminectomy and micro-surgical excision and it was reported as a case of myxopapillary ependymoma. However, immunohistochemical (IHC) stains were positive for GBM g

APA, Harvard, Vancouver, ISO, and other styles

11

King, Andrew T., Scott A. Rutherford, Charlotte Hammerbeck-Ward, et al. "High-Grade Glioma is not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient." Neurosurgery 83, no. 2 (2017): 193–96. http://dx.doi.org/10.1093/neuros/nyx374.

Full text

Abstract:

Abstract BACKGROUND The Manchester criteria for neurofibromatosis type 2 (NF2) include a range of tumors, and gliomas were incorporated in the original description. The gliomas are now widely accepted to be predominantly spinal cord ependymomas. OBJECTIVE To determine whether these gliomas include any cases of malignant glioma (WHO grade III and IV) through a database review. METHODS The prospective database consists of 1253 patients with NF2. 1009 are known to be alive at last follow-up. RESULTS There was a single case of glioblastoma multiforme (GBM; World Health Organization grade IV) in th

APA, Harvard, Vancouver, ISO, and other styles

12

Zhao, Zheng, Ke-Nan Zhang, Rui-Chao Chai, et al. "ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme." Disease Markers 2019 (January 8, 2019): 1–12. http://dx.doi.org/10.1155/2019/1802620.

Full text

Abstract:

Background. Researches on immunotherapy of glioblastoma multiforme (GBM, WHO grade IV) have increased exponentially in recent years. As a targeted therapy, a series of biomarkers have been identified in local tumor tissue, while circulating marker which could be detected in the body fluids is still lacking. ADAMTSL4, a secreted glycoprotein, was earlier found to play a critical role in a prognostic signature for primary GBM (pGBM). We aimed to investigate the role of ADAMTSL4 at transcriptome level and its relationship with clinical practice in pGBM. Methods. A cohort of 88 pGBM patients with

APA, Harvard, Vancouver, ISO, and other styles

13

Stadlbauer, Andreas, Thilo Hammen, Michael Buchfelder, et al. "Differences in Metabolism of Fiber Tract Alterations in Gliomas." Neurosurgery 71, no. 2 (2012): 454–63. http://dx.doi.org/10.1227/neu.0b013e318258e332.

Full text

Abstract:

Abstract BACKGROUND: Gliomas propagate diffusely throughout and along white matter structures. Glioma-related changes in structural integrity and metabolism are not detectable by standard magnetic resonance (MR) imaging. OBJECTIVE: To investigate differences in the metabolism of fiber tract alterations between gliomas grade II to IV by correlation of fiber density values with metabolite concentrations measured by fiber density mapping and MR spectroscopic imaging. METHODS: Fiber density mapping and MR spectroscopic imaging were performed in 48 patients with gliomas WHO grade II to IV. Fiber de

APA, Harvard, Vancouver, ISO, and other styles

14

Elliott, Willie, Nandini Gurramkonda, Maheedhara R. Guda, Andrew J. Tsung, and Kiran K. Velpula. "Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme." Cells 14, no. 10 (2025): 755. https://doi.org/10.3390/cells14100755.

Full text

Abstract:

Glioblastoma, IDH wild-type WHO Grade IV, is a devastating diagnosis in pediatric and adult populations with a poor prognosis and median overall survival of less than two years. Despite the advent of the Stupp protocol and advances in neurosurgical tumor resection techniques, there has been minimal change to both the quantity and quality of life in individuals diagnosed. Provided the extensive research on survivin’s association with glioblastoma tumor microenvironment, this review suggests that priming the individual’s immune systems to the tumor-promoting protein may reduce tumor burden throu

APA, Harvard, Vancouver, ISO, and other styles

15

Nesselhut, Jan, Dagmar Marx, Nicole Cillien, et al. "Comparison of early versus late onset of cellular immunotherapy in glioblastoma multiforme WHO IV." Journal of Clinical Oncology 35, no. 15_suppl (2017): e13531-e13531. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13531.

Full text

Abstract:

e13531 Background: Glioblastoma multiforme (GBM WHO grade IV glioma) is an aggressive disease with an unfavorable prognosis. The current first line treatment comprises radical operation and radiotherapy combined with temozolomide chemotherapy (Stupp protocol). After failure of first-line therapy there is currently no effective therapy. Here we report that dendritic cell therapy prolongs the survival for patients with newly diagnosed GBM V. Preliminary results show that adding checkpoint blockade with Nivolumab may cause a secondary therapy response. Methods: After isolating monocytes from peri

APA, Harvard, Vancouver, ISO, and other styles

16

Jeibmann, Astrid, Martin Hasselblatt, Stefan Pfister, et al. "From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior." Journal of Neurosurgery: Pediatrics 4, no. 5 (2009): 475–78. http://dx.doi.org/10.3171/2009.6.peds097.

Full text

Abstract:

The prognosis in children harboring a glioblastoma multiforme (GBM) is usually poor. Few GBMs in children, however, seem to respond quite well to adjuvant chemotherapy. The biological basis for such chemotherapy sensitivity remains uncertain. In this paper the authors report the case of a 2-month-old girl with a histologically confirmed GBM (WHO Grade IV) in whom chemotherapy was accompanied by differentiation of the malignant primary tumor into a typical gangliocytoma (WHO Grade I) showing ganglioid differentiation and expression of neuronal markers synaptophysin, neurofilament, and NeuN as w

APA, Harvard, Vancouver, ISO, and other styles

17

Nesselhut, J., T. Nesselhut, R. Chang, et al. "Dendritic cell therapy in glioblastoma multiforme." Journal of Clinical Oncology 25, no. 18_suppl (2007): 3065. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3065.

Full text

Abstract:

3065 Background: Malignant brain tumors belong to the tumors with unfavorable prognosis. The most aggressive form, glioblastoma multiforme (GBM WHO grade IV glioma), is categorized as incurable with median survivals less than 12–18 months and 90–95% of patients surviving less than 2 years. Here we show that immunotherapy with monocyte-derived dendritic cells (MoDC) can induce a clinical response in advanced GMB, especially when combined with the non human pathogenic oncolytic virus NDV (New Castle Disease Virus). Methods: After isolating monocytes from peripheral blood of n=21 patients dendrit

APA, Harvard, Vancouver, ISO, and other styles

18

Carrillo, Jose A., Frank P. K. Hsu, Johnny Delashaw, and Daniela Bota. "Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab." Reviews in Health Care 5, no. 1 (2014): 23–32. http://dx.doi.org/10.7175/rhc.v5i1.668.

Full text

Abstract:

Despite recent advances in the treatment of malignant gliomas (World Health Organization grade III and grade IV tumors- Glioblastoma Multiforme, Anaplastic Astrocytoma and Anaplastic Oligodendroglioma), the overall prognosis remains poor. Tumor recurrence in malignant glioma is inevitable, and associated with reduced overall survival (OS). Bevacizumab is approved for use in progressive GBM as a second line treatment, and is associated with improvements in progression free survival (PFS). However, all GBM patients eventually recur on bevacizumab therapy, with a very short OS after bevacizumab f

APA, Harvard, Vancouver, ISO, and other styles

19

Sayed, Basant H., Samia M. Gabal, Ahmed M. Abdalaziz, and Dalia Abd El-Kareem. "Nuclear Factor-Kappa B in Gliomas as a Predictive Factor for Tumor Recurrence – A Clinicopathological Study." Open Access Macedonian Journal of Medical Sciences 11, A (2023): 221–27. http://dx.doi.org/10.3889/oamjms.2023.11085.

Full text

Abstract:

BACKGROUND: Glioma is the most common primary malignant brain tumor. Nuclear factor κB (NF-κB) has emerged as a regulator of the malignant phenotype in glioma, and in particular glioblastoma multiforme, with clear relation to tumor size, recurrence, and invasiveness. AIM: The aim of the study was to study the analysis of NF-κB expression in gliomas of different histologic types and grades and its correlation with various clinicopathologic indicators. METHODS: One hundred and ten paraffin blocks of glioma cases classified according to WHO classification into 14 (12.7%) cases of Grade I pilocyti

APA, Harvard, Vancouver, ISO, and other styles

20

Lechpammer, Mirna, Rohan Rao, Sanjit Shah, et al. "Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers." Cancers 14, no. 7 (2022): 1627. http://dx.doi.org/10.3390/cancers14071627.

Full text

Abstract:

Glioblastoma, or glioblastoma multiforme (GBM, WHO Grade IV), is a highly aggressive adult glioma. Despite extensive efforts to improve treatment, the current standard-of-care (SOC) regimen, which consists of maximal resection, radiotherapy, and temozolomide (TMZ), achieves only a 12–15 month survival. The clinical improvements achieved through immunotherapy in several extracranial solid tumors, including non-small-cell lung cancer, melanoma, and non-Hodgkin lymphoma, inspired investigations to pursue various immunotherapeutic interventions in adult glioblastoma patients. Despite some encourag

APA, Harvard, Vancouver, ISO, and other styles

21

Kalita, O., M. Hajduch, R. Trojanec, et al. "P08.70 Prognostic and predictive factors in primary Glioblastoma Multiforme WHO grade IV patients with resection: A single-institution study." Neuro-Oncology 18, suppl_4 (2016): iv58. http://dx.doi.org/10.1093/neuonc/now188.203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Nasser, José Augusto, Asdrúbal Falavigna, Fernando Ferraz, Gregory Duigou, and Jeffrey Bruce. "Transcription analysis of TIMP-1 and NM23-h1 genes in glioma cell invasion." Arquivos de Neuro-Psiquiatria 64, no. 3b (2006): 774–80. http://dx.doi.org/10.1590/s0004-282x2006000500014.

Full text

Abstract:

PURPOSE: To evaluate using transcription analysis the presence and importance of two genes: NM23-H1 and TIMP-1 on control of tumor cell invasion in diffuse astrocytomas (WHO II) and glioblastoma multiforme (WHO IV). METHOD: Northern blot analysis of NM23-H1 and TIMP-1 was performed. Eight diffuse astrocytomas and 19 glioblastomas (WHO IV) were analyzed to determine if TIMP-1 and NM23-H1 were candidates to inhibition of tumor cell invasion quantitated RNA levels. The samples were collected directly from operating room. Total cellular RNA was extracted from frozen tissue samples using guanidiniu

APA, Harvard, Vancouver, ISO, and other styles

23

Amend, Christina, James Stadler, Shahriar Salamat, Erik Dedekam, Angela Waanders, and Nitin Wadhwani. "HGG-43. CONGENITAL GLIOBLASTOMA MULTIFORME: A CASE REPORT OF A RARE PEDIATRIC BRAIN TUMOR, MOLECULAR ANALYSIS, AND REVIEW OF THE LITERATURE." Neuro-Oncology 22, Supplement_3 (2020): iii351. http://dx.doi.org/10.1093/neuonc/noaa222.324.

Full text

Abstract:

Abstract Congenital brain tumors are rare, accounting for less than 4% of all pediatric brain tumors. Congenital glioblastoma multiforme (GBM) is rarer still, accounting for 3–15% of congenital brain tumors. There is literature to suggest that these tumors differ from pediatric and adult GBM clinically and molecularly, and as such should be treated as their own distinct entity. Our case is a 4 week old male who initially presented to his pediatrician for enlarging head circumference and upward gaze palsy. An MRI was obtained revealing a right parietal mass. He underwent gross total resection t

APA, Harvard, Vancouver, ISO, and other styles

24

Vavruch, Ludek, Bo Nordenskjöld, John Carstensen, and Sverker Eneström. "Prognostic value of flow cytometry and correlation to some conventional prognostic factors: a retrospective study of archival specimens of 134 astrocytomas." Journal of Neurosurgery 85, no. 1 (1996): 146–51. http://dx.doi.org/10.3171/jns.1996.85.1.0146.

Full text

Abstract:

✓ The S-phase fraction and the DNA ploidy type in 134 astrocytomas (18 Grade II, 46 Grade III, and 70 Grade IV astrocytomas) were studied using flow cytometry in a retrospective study of archival tumor specimens. A high grade of malignancy was associated with both a high S-phase fraction (p < 0.0001) and an aneuploid DNA pattern (p < 0.0001). There was no aneuploid DNA pattern found in the fibrillary astrocytomas (World Health Organization (WHO) Grade II); whereas the aneuploid pattern was observed in 80% of all the glioblastomas multiforme (WHO Grade IV). The age and gender of the patie

APA, Harvard, Vancouver, ISO, and other styles

25

Stoyanov, George St, and Deyan L. Dzhenkov. "On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics." Folia Medica 60, no. 1 (2018): 48–66. http://dx.doi.org/10.1515/folmed-2017-0069.

Full text

Abstract:

AbstractGlioblastoma multiforme(GBM) is a grade IV WHO malignant tumor with astrocytic differentiation. As one of the most common clinically diagnosed central nervous system (CNS) oncological entries, there have been a wide variety of historical reports of the description and evolution of ideas regarding these tumors.The first recorded reports of gliomas were given in British scientific reports, by Berns in 1800 and in 1804 by Abernety, with the first comprehensive histomorphological description being given in 1865 by Rudolf Virchow. In 1926 Percival Bailey and Harvey Cushing gave the base for

APA, Harvard, Vancouver, ISO, and other styles

26

Desjardins, A., D. A. Reardon, J. A. Quinn, et al. "Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas." Journal of Clinical Oncology 24, no. 18_suppl (2006): 1573. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1573.

Full text

Abstract:

1573 Background: We evaluated the combination of imatinib mesylate (Gleevec) and hydroxyurea in WHO grade III malignant gliomas following the encouraging response of this combination demonstrated in glioblastoma multiforme. Methods: Eligibility: adult patients with recurrent/relapsing AA or AO with measurable disease; 2 weeks since surgical resection or 4 weeks since radiotherapy or chemotherapy; Karnofsky 60% and adequate organ function. Imatinib and hydroxyurea were given orally daily. Imatinib was administered at 400 mg daily to patients not on enzyme inducing antiepileptic drugs (EIAED) wh

APA, Harvard, Vancouver, ISO, and other styles

27

Zaheen Shibli, Aurangzeb Kalhoro, Kashif Ahmed, and Abdul Sattar M. Hashim. "PET-CT Guided Gamma Knife Radiosurgery for Recurrent Glioblastoma Multiforme Recurrent Cases in Pakistan." Pakistan Journal Of Neurological Surgery 27, no. 2 (2023): 251–58. http://dx.doi.org/10.36552/pjns.v27i2.851.

Full text

Abstract:

Objective: The treatment of recurrent Glioblastoma Multiforme (r-GBM) poses a significant confronts to neurosurgeons. This study was conducted to assess the effectiveness of PET-CT-guided Gamma Knife radiosurgery (GKRS) in treating r-GBM. The purpose of the study is to determine the outcome of this treatment approach. Materials and Methods: Retrospective descriptive research was supervised at the Neurospinal and Cancer Care Institute, Karachi Pakistan between June 2017 to August 2022. The study comprised patients with biopsy-confirmed Grade IV Glioblastoma Multiforme who experienced recurrence

APA, Harvard, Vancouver, ISO, and other styles

28

Dhungel, Laxmi, Mandy E. Rowsey, Cayla Harris, and Drazen Raucher. "Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy." Molecules 29, no. 4 (2024): 840. http://dx.doi.org/10.3390/molecules29040840.

Full text

Abstract:

Glioblastoma multiforme (GBM), a grade IV (WHO classification) malignant brain tumor, poses significant challenges in treatment. The current standard treatment involves surgical tumor removal followed by radiation and chemotherapeutic interventions. However, despite these efforts, the median survival for GBM patients remains low. Temozolomide, an alkylating agent capable of crossing the blood–brain barrier, is currently the primary drug for GBM treatment. Its efficacy, however, is limited, leading to the exploration of combination treatments. In this study, we have investigated the synergistic

APA, Harvard, Vancouver, ISO, and other styles

29

Robilliard, L. D., C. MacDonald, C. E. Angel, G. J. Finlay, W. Joseph, and E. S. Graham. "P12.02 Glioblastoma Multiforme immunological blockades and the implications of glioma cancer stem cells." Neuro-Oncology 21, Supplement_3 (2019): iii59. http://dx.doi.org/10.1093/neuonc/noz126.213.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma Multiforme (GBM) is classified as a WHO grade IV astrocytoma that continues to circumvent classical and novel chemo-, radio- and immuno-therapies. The recent FDA approvals for the use of targeted immunotherapies against inhibitory checkpoint ligands (for melanoma; ipilimumab and nivolumab) have brought the use of monoclonal antibody therapies to the forefront of GBM research. However, poor immunological responses, exemplified by down-regulation of anti-tumour T-cell activity, and up-regulation of immunosuppressive cells and secreted factors within the tumour mi

APA, Harvard, Vancouver, ISO, and other styles

30

Katkar, Rujuta Baban, and Raju Vaddepally. "Glioblastoma Multiforme and Papillary Thyroid Carcinoma: Rare Combination of Primary Malignancies." Journal of the Endocrine Society 5, Supplement_1 (2021): A890. http://dx.doi.org/10.1210/jendso/bvab048.1817.

Full text

Abstract:

Abstract Introduction: Studies have reported thyroid cancer patients are potentially at 30% increased risk of getting second primary cancer when compared to the general population. We are describing a young Caucasian male patient who was diagnosed with two synchronous cancers, papillary thyroid cancer (PTC) and glioblastoma multiforme (GBM). Case Report: A 52 year old Caucasian male with past medical history of hypertension, partial right thyroidectomy in 1999 for thyroid nodular disease, and postsurgical hypothyroidism on levothyroxine. He underwent FNA of left thyroid nodule found on routine

APA, Harvard, Vancouver, ISO, and other styles

31

Reulen, Hans-Juergen, Gabriele Poepperl, Claudia Goetz, et al. "Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy." Journal of Neurosurgery 123, no. 3 (2015): 760–70. http://dx.doi.org/10.3171/2014.12.jns142168.

Full text

Abstract:

OBJECT The aim in this study was to present long-term results regarding overall survival (OS), adverse effects, and toxicity following fractionated intracavitary radioimmunotherapy (RIT) with iodine-131− or yttrium-90−labeled anti-tenascin monoclonal antibody (131I-mAB or 90Y-mAB) for the treatment of patients with malignant glioma. METHODS In 55 patients (15 patients with WHO Grade III anaplastic astrocytoma [AA] and 40 patients with WHO Grade IV glioblastoma multiforme [GBM]) following tumor resection and conventional radiotherapy, radioimmunoconjugate was introduced into the postoperative r

APA, Harvard, Vancouver, ISO, and other styles

32

Ryskalin, Larisa, Gloria Lazzeri, Marina Flaibani, et al. "mTOR-Dependent Cell Proliferation in the Brain." BioMed Research International 2017 (2017): 1–14. http://dx.doi.org/10.1155/2017/7082696.

Full text

Abstract:

The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth, proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways. Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors. This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. Glio

APA, Harvard, Vancouver, ISO, and other styles

33

Santare, John, David Sosidko, Claire Dawyot, et al. "NCOG-12. TREATMENT AND MORTALITY OF PRIMARY BRAIN TUMORS: A SINGLE CENTER OBSERVATIONAL STUDY OF GLIOBLASTOMAS AND ASTROCYTOMAS." Neuro-Oncology 26, Supplement_8 (2024): viii226. http://dx.doi.org/10.1093/neuonc/noae165.0894.

Full text

Abstract:

Abstract Glioblastoma multiforme (GBM) is a WHO grade IV malignant tumor with a relatively poor prognosis (median survival of 15 months). Astrocytomas are WHO grade I-III tumors with a better prognosis than GBM; their median survival ranging from 2-10 years. We assessed the response to various mainstay treatment modalities in patients with GBM and astrocytoma, expecting to find that surgery and stereotactic radiation (SRS) treatment confer greater survival benefits than non-surgical and whole brain radiation (WBRT) options. We analyzed 108 patients at St. Luke’s University Health Network (SLUH

APA, Harvard, Vancouver, ISO, and other styles

34

Majkowska-Pilip, Agnieszka, Przemysław Koźmiński, Anna Wawrzynowska, Tadeusz Budlewski, Bogusław Kostkiewicz, and Ewa Gniazdowska. "Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with 99mTc and 177Lu as Potential Receptor Radiopharmaceuticals." Molecules 23, no. 10 (2018): 2542. http://dx.doi.org/10.3390/molecules23102542.

Full text

Abstract:

Gliomas, particularly WHO grade IV glioblastoma multiforme, are one of the most common and aggressive primary tumors of the central nervous system. The neuropeptide, substance P (SP), is the physiological ligand of the neurokinin-1 (NK-1) receptor that is consistently overexpressed in glioblastoma cells. The aim of this work was to study physico-chemical and biological properties of different SP analogues labeled with technetium-99m and lutetium-177 radionuclides. The synthesized compounds were characterized in vitro by partition coefficients (logP) and their stability was investigated in vari

APA, Harvard, Vancouver, ISO, and other styles

35

Calubayan, John Michael, and Paul Vincent Opinaldo. "SPCR-01 CONCURRENT WOUNDED GLIOMA SYNDROME AND DISTANT WOUNDED GLIOMA SYNDROME FOLLOWING A GROSS TOTAL RESECTION OF GLIOBLASTOMA MULTIFORME - A CASE REPORT." Neuro-Oncology Advances 5, Supplement_3 (2023): iii26. http://dx.doi.org/10.1093/noajnl/vdad070.102.

Full text

Abstract:

Abstract Surgery is the initial form of treatment for glioblastoma, and a maximum resection without impairing neurological function improves survival. Wounded Glioma Syndrome (WGS) is a clinical picture observed after the resection of high-grade tumors. This syndrome, developing within hours or a few days after glioma surgery, is characterized by hemorrhage into the surgical bed and cerebral edema, and at times occurring in areas distant from the site of the resection, i.e., Distant WGS. We report a case of an elderly male presenting with an acute-onset left leg weakness, with a large peripher

APA, Harvard, Vancouver, ISO, and other styles

36

Calubayan, John Michael, and Paul Vincent Opinaldo. "NCMP-13. CONCURRENT WOUNDED GLIOMA SYNDROME AND DISTANT WOUNDED GLIOMA SYNDROME FOLLOWING A GROSS TOTAL RESECTION OF GLIOBLASTOMA MULTIFORME – A CASE REPORT." Neuro-Oncology 25, Supplement_5 (2023): v209. http://dx.doi.org/10.1093/neuonc/noad179.0797.

Full text

Abstract:

Abstract Surgery is the initial form of treatment for glioblastoma, and a maximum resection without impairing neurological function improves survival. Wounded Glioma Syndrome (WGS) is a clinical picture observed after the resection of high-grade tumors. This syndrome, developing within hours or a few days after glioma surgery, is characterized by hemorrhage into the surgical bed and cerebral edema, and at times occurring in areas distant from the site of the resection, i.e., Distant WGS. We report a case of an elderly male presenting with an acute-onset left leg weakness, with a large peripher

APA, Harvard, Vancouver, ISO, and other styles

37

Hasan, Md Motasimul, Md Lylatul Kadir, Kazi Hafiz Uddin, et al. "Correlation between Magnetic Resonance Imaging (MRI) Findings with Histological Grading of Patients with Supratentorial Diffusely Infiltrating Astrocytomas." Bangladesh Journal of Neurosurgery 10, no. 1 (2020): 67–74. http://dx.doi.org/10.3329/bjns.v10i1.49165.

Full text

Abstract:

Data regarding the impact of MRI for diagnosis and staging of brain tumors in our population is sparse. Thus, the purpose of this study is to determine the efficacy of MRI in preoperative diagnosis of primary intra-axial brain tumors and to determine its diagnostic accuracy in grading of gliomas in our population, correlated with histopathological (hematoxylin & eosin stain) findings taking as gold standard. There has been extensive works in developed countries regarding the diagnostic effectiveness of MRI. But only a few works have been done in our country. To be very particular, little w

APA, Harvard, Vancouver, ISO, and other styles

38

Gharib, Hawbir, Ari Nadhim, and Bamo Muhsin. "SURVIVAL OUTCOMES AMONG PATIENTS WITH HIGH-GRADE GLIOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY." JOURNAL OF SULAIMANI MEDICAL COLLEGE 13, no. 3 (2023): 11. http://dx.doi.org/10.17656/jsmc.10414.

Full text

Abstract:

BackgroundThe prognosis for glioma patients is poor, despite recent advances in diagnosis and treatment. Understanding Glioma’s clinical characteristics and predictive factors is crucial for patient treatment and management. ObjectivesTo assess the survival duration of HGG patients at a single facility and to discover clinical determinants of treatment outcome in HGG treated with a combined modality approach in Zhianawa Cancer Center. Patients and MethodsThis study included 133 patients with high-grade gliomas diagnosed between January 2015 and January 2020; these patients were ref

APA, Harvard, Vancouver, ISO, and other styles

39

Kartika, Dewa, and Baskoro Nurdopo. "Laporan Kasus Butterfly gliobasltoma pada Laki-Laki Usia 24 Tahun." Medica Hospitalia : Journal of Clinical Medicine 8, no. 3 (2021): 395–411. http://dx.doi.org/10.36408/mhjcm.v8i3.678.

Full text

Abstract:

Pendahuluan Butterfly Glioma adalah high grade astrocytoma, biasanya glioblastoma (WHO grade IV), yang melintasi garis tengah melalui corpus callosum. Komissura white matter lainnya kadang juga terlibat. Istilah kupu-kupu mengacu pada ekstensi yang melewati garis tengah seperti sayap. Butterfly Glioma paling sering terjadi di lobus frontal, melintasi garis tengah melalui genu corpus callosum, namun butterfly glioma posterior kadang juga ditemui. Laporan kasus Seorang pasien laki-laki usia 24 tahun dengan keluhan utama 9 bulan, yang lalu. Penglihatan kabur, konsentrasi menurun

APA, Harvard, Vancouver, ISO, and other styles

40

Izumi, Clarice, Helen Julie Laure, Nayara Gonçalves Barbosa, et al. "Sequesterpene Lactones Isolated from a Brazilian Cerrado Plant (Eremanthus spp.) as Anti-Proliferative Compounds, Characterized by Functional and Proteomic Analysis, Are Candidates for New Therapeutics in Glioblastoma." International Journal of Molecular Sciences 21, no. 13 (2020): 4713. http://dx.doi.org/10.3390/ijms21134713.

Full text

Abstract:

Gliomas are responsible for more than 60% of all primary brain tumors. Glioblastoma multiforme (GBM), a grade IV tumor (WHO), is one of the most frequent and malignant gliomas. Despite two decades of advances in the discovery of new markers for GBM, the chemotherapy of choice falls to temozolomide after surgery and radiotherapy, which are not enough to increase the survival of patients to more than 15 months. It is urgent to discover new anti-glioma compounds. Many compounds derived from natural products have been used in the development of anti-tumor drugs. In this work, we have screened six

APA, Harvard, Vancouver, ISO, and other styles

41

Lone, Mohd Iqbal, Tazeen Jeelani, Gazanfar Rashid, Nusrat Bashir, and Dekyong Angmo. "Intraoperative squash cytology and histopathological correlation of primary temporal lobe lesions: a 6 year study at tertiary care centre of Kashmir, India." International Journal of Research in Medical Sciences 6, no. 6 (2018): 2148. http://dx.doi.org/10.18203/2320-6012.ijrms20182304.

Full text

Abstract:

Background: Central nervous system (CNS) tumors constitute about 1-2% of all the tumors. They are the 6th most common tumors in adults and 2nd most common among childhood tumors. Gliomas are the most common CNS neoplasms. In addition to gliomas temporal lobe has predilection for some peculiar tumor subtypes having good prognosis, including pleomorphic xanthoastrocytoma (PXA), low grade astrocytic tumors and dysembryoplastic neuroepithelial tumor (DNET) in children.Methods: Study was conducted in the department of pathology Sher-e-Kashmir institute of medical sciences (SKIMS) Soura, Srinagar Ka

APA, Harvard, Vancouver, ISO, and other styles

42

Jensen, Per, Li Feng, Ian Law, et al. "TSPO imaging in glioblastoma multiforme: A direct comparison between 123ICLINDE-SPECT, 18F-FET PET and gadolinium-enhanced MRI." Journal of Nuclear Medecine 56, no. 9 (2015): 1386–90. https://doi.org/10.2967/jnumed.115.158998.

Full text

Abstract:

Here we compare TSPO imaging using 123 I-CLINDE and amino acid transport imaging using 18 F-FET and investigate if 123 I-CLINDE is superior to 18 F-FET in predictingprogression of glioblastoma multiforme (GBM) at follow up. <strong>Methods</strong>  Three patients with WHO grade IV GBM were scanned with 123 I-CLINDE SPECT, 18 F-FET PET and Gadolinium enhanced magnetic resonance imaging (gadolinium-MRI). Molecular imaging data were compared to follow-up gadolinium-MRI or contrast enhanced computed tomography (CE-CT). <strong>Results</strong>  The percentage overlap

APA, Harvard, Vancouver, ISO, and other styles

43

Pasquini, Luca, Antonio Napolitano, Emanuela Tagliente, et al. "Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM." Journal of Personalized Medicine 11, no. 4 (2021): 290. http://dx.doi.org/10.3390/jpm11040290.

Full text

Abstract:

Isocitrate dehydrogenase (IDH) mutant and wildtype glioblastoma multiforme (GBM) often show overlapping features on magnetic resonance imaging (MRI), representing a diagnostic challenge. Deep learning showed promising results for IDH identification in mixed low/high grade glioma populations; however, a GBM-specific model is still lacking in the literature. Our aim was to develop a GBM-tailored deep-learning model for IDH prediction by applying convoluted neural networks (CNN) on multiparametric MRI. We selected 100 adult patients with pathologically demonstrated WHO grade IV gliomas and IDH te

APA, Harvard, Vancouver, ISO, and other styles

44

Krishnan, Shyam Sundar, Shanmugam Muthiah, Shilpa Rao, Suganthi Srinivasan Salem, Vasudevan Chakravarthy Madabhushi, and Anita Mahadevan. "Mindbomb Homolog-1 Index in the Prognosis of High-Grade Glioma and Its Clinicopathological Correlation." Journal of Neurosciences in Rural Practice 10, no. 02 (2019): 185–93. http://dx.doi.org/10.4103/jnrp.jnrp_374_18.

Full text

Abstract:

ABSTRACT Introduction: Gliomas are the most common brain tumors in adults originating from the glial cells. Glioblastoma multiforme is the most malignant and frequent among all gliomas. In recent years, the antibody Mindbomb Homolog-1 (MIB-1) has evolved as a measure of the proliferative nature of the glial tumors. This study aims to investigate the MIB-1 index value as an independent prognostic factor in high-grade gliomas and its correlation with outcome and survival. Materials and Methods: Mean MIB-1 index was determined in 51 high-grade glioma tissue samples in formalin. Its correlation wi

APA, Harvard, Vancouver, ISO, and other styles

45

Heery, C. R., A. Desjardins, J. A. Quinn, et al. "Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 11504. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.11504.

Full text

Abstract:

11504 Background: Treatment of patients with newly diagnosed malignant glioma using Gliadel wafer implantation at initial surgery has been shown to increase survival (Westphal et al 2003). Similarly, administration of temozolomide during and after radiotherapy has also been shown to increase survival in this patient population (Stupp et al 2005). Accordingly use of both Gliadel and temozolomide may be advantageous for these patients although it is possible that the toxicity of these two approaches used together might be prohibitive. Methods: The Preston Robert Tisch Brain Tumor Center at Duke

APA, Harvard, Vancouver, ISO, and other styles

46

Yang, Yunan, Reinier Hernandez, Jun Rao, et al. "Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas." Proceedings of the National Academy of Sciences 112, no. 47 (2015): E6525—E6534. http://dx.doi.org/10.1073/pnas.1502648112.

Full text

Abstract:

Given the highly heterogeneous character of brain malignancies and the associated implication for its proper diagnosis and treatment, finding biomarkers that better characterize this disease from a molecular standpoint is imperative. In this study, we evaluated CD146 as a potential molecular target for diagnosis and targeted therapy of glioblastoma multiforme (GBM), the most common and lethal brain malignancy. YY146, an anti-CD146 monoclonal antibody, was generated and radiolabeled for noninvasive positron-emission tomography (PET) imaging of orthotopic GBM models. 64Cu-labeled YY146 preferent

APA, Harvard, Vancouver, ISO, and other styles

47

Mott, Ryan T., Kristi C. Turner, Darell D. Bigner, and Roger E. McLendon. "Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas." Journal of Neurosurgery 108, no. 2 (2008): 330–35. http://dx.doi.org/10.3171/jns/2008/108/2/0330.

Full text

Abstract:

Object DIFFUSELY infiltrating astrocytomas are the most common primary brain tumors. As a group, they demonstrate an inherent tendency toward malignant progression. Histological grading using the guidelines of the World Health Organization (WHO) remains the gold standard for predicting the biological behavior of these tumors. Although useful, this grading system is often limited due to small sample sizes and the subjectivity in interpretation. Given the important roles for EGFR and PTEN in the malignant progression of astrocytomas, the authors hypothesized that the fraction of tumor cells with

APA, Harvard, Vancouver, ISO, and other styles

48

McGirt, Matthew J., Kaisorn L. Chaichana, Muraya Gathinji, et al. "Independent association of extent of resection with survival in patients with malignant brain astrocytoma." Journal of Neurosurgery 110, no. 1 (2009): 156–62. http://dx.doi.org/10.3171/2008.4.17536.

Full text

Abstract:

Object With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival. In this study, the authors investigate this issue after primary and revision resection of these lesions. Methods The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006. Patients with deep-seated or unresectable lesions were excluded. Based on MR imaging results obtained < 48 hours

APA, Harvard, Vancouver, ISO, and other styles

49

Natt, Muhammad Aqeel, Ahtesham Khizar, Haseeb Mehmood Qadri, et al. "Free-hand Frameless Pinless Electromagnetic-Navigation (AXIEMTM)-Guided Brain Lesion Biopsies: An Institution Based Experience from a Low-Middle-Income Country." Pakistan Journal of Medical Sciences 40, no. 12(PINS) (2024): S6—S14. http://dx.doi.org/10.12669/pjms.40.12(pins).11106.

Full text

Abstract:

Objectives: To evaluate the precision and safety of a novel technique of free-hand frameless pinless AXIEMTM-based navigation guided biopsy of deep-seated brain lesions in a low-middle income country. Methods: This retrospective study included 45 patients who underwent free-hand frameless pinless AXIEMTM-based navigation guided biopsy of deep-seated brain lesions using the Medtronic-Stealth S7 system over a 5-year period (January 2019 to December 2023) at the Department of Neurosurgery, Punjab Institute of Neurosciences, Lahore, Pakistan. Results: A total of 45 patients were included in this s

APA, Harvard, Vancouver, ISO, and other styles

50

Kewan, Tariq Zuheir, Fahrettin Covut, Bicky Thapa, Timothy Peter Spiro, Abdo S. Haddad, and Hamed Daw. "Impact of next-generation sequencing (NGS) in patients with high grade glioma." Journal of Clinical Oncology 37, no. 15_suppl (2019): e13541-e13541. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13541.

Full text

Abstract:

e13541 Background: Clinical utility of NGS in high grade glioma patients remain debatable. Methods: We reviewed patients who underwent Foundation One NGS between 7/2013 and 10/2018 after high-grade glioma diagnosis at Cleveland Clinic. Overall survival (OS) and progression free survival (PFS) were estimated by the Kaplan-Meier method and compared by log-rank test. Cox regression analysis was performed to identify predictors of OS. Results: We identified 153 patients, 130 (85%) had glioblastoma multiforme (GBM) and 23 (15%) had grade III glioma, 51 (33%) were female, and median age at diagnosis

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!